Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Share:
Related ARIA
Watch These 7 Huge Call Purchases In Tuesday Trade
Technical Alert: Finding Resistance In Ariad Pharmaceuticlas After Q2 Report
ARIAD completes NDA submission for brigatinib, requests accelerated review (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but lowered its price target from $27.00 to $23.00.

Jefferies & Company noted, “FDA approves Iclusig in CML/Ph+ ALL pts resistant/intolerant to TKIs, ~3 months earlier (PDUFA date of 3/27/13). Boxed warning on previously undisclosed safety issues (potential liver toxicity, arterial thrombosis) is surprising, although it's hard to know whether these are due to Iclusig, underlying disease, or both given single-arm PACE trial (& 1st-line EPIC interim data comparing ponatinib to imatinib expected ~1H14).”

Ariad Pharmaceuticals closed on Friday at $18.93.

Latest Ratings for ARIA

DateFirmActionFromTo
Jul 2016BarclaysMaintainsUnderweight
May 2016Cowen & CompanyUpgradesMarket PerformOutperform
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

View Comments and Join the Discussion!